{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:44:19Z","timestamp":1773434659291,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and prevalence) and associated costs of select comorbidities in RA patients: anemia, malignancy, venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and infections, stratified by history of disease\u2010modifying antirheumatic drug (DMARD) exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From the IQVIA PharMetrics\u00ae Plus database, we selected adult patients with RA (2 or more RA diagnostic codes at least 30\u2009days apart) at initiation of a new DMARD (DMARD\u2010na\u00efve), after the first conventional synthetic DMARD (csDMARD) or after the first biologic DMARD (bDMARD). We assessed pre\u2010index prevalence (percentage) and on\u2010treatment incidence (per 100 patient\u2010years [P100PY]) of the aforementioned comorbidities. For patients with versus without incident conditions, we compared total all\u2010cause health care costs as unadjusted and adjusted for baseline characteristics and health care costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prior to initiating a new treatment, among DMARD\u2010na\u00efve patients (N\u00a0=\u00a028,201), csDMARD switchers (N\u00a0=\u00a07,816), or bDMARD switchers (N\u00a0=\u00a04,656), the overall prevalence ranged from 14.1% to 16.2% (anemia), from 1.3% to 5.2% (malignancy, evaluated in csDMARD and bDMARD switchers), from 1.5% to 2.1% (VTE), from 1.8% to 2.9% (MACE), and from 66.6% to 76.1% (infections). Once on index treatment, overall incidence (P100PY) among the cohorts ranged from 6.9 to 8.9 (anemia), from 2.0 to 2.3 (malignancy), from 0.7 to 0.9 (VTE), from 1.6 to 2.0 (MACE), and from 77.4 to 87.7 (infections). The incident comorbidities (except herpes zoster) were associated with increased adjusted health care costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anemia, malignancy, VTE, MACE, and infections affect patients with RA at all stages of their treatment journey and are associated with increased health care costs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11376","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T10:52:42Z","timestamp":1637232762000},"page":"473-482","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States"],"prefix":"10.1002","volume":"4","author":[{"given":"Robin K.","family":"Dore","sequence":"first","affiliation":[{"name":"Private practice  Tustin California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-8805","authenticated-orcid":false,"given":"Jenya N.","family":"Antonova","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakkarin","family":"Burudpakdee","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting  Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Chang","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdaliz","family":"Gorritz","sequence":"additional","affiliation":[{"name":"IQVIA, Plymouth Meeting  Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California"},{"name":"Division of Immunology and Rheumatology Stanford University  Stanford California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key287"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40841"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0430-0"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0728-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0064-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22039"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2492-7"},{"issue":"539","key":"e_1_2_6_11_1","first-page":"e7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease\u2010modifying antirheumatic drugs","volume":"128","author":"Kim SC","year":"2015","journal-title":"Am J Med"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210275"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8010015"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.012"},{"key":"e_1_2_6_17_1","first-page":"289","article-title":"Sulfasalazine\u2010induced pancytopenia indicative of bone marrow suppression: a case report","volume":"5","author":"Alanazi AS","year":"2014","journal-title":"J Med Cases"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep406"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/jpp.JPP_93_16"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.11.033"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S89331"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-10-59"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1571498"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22860"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex394"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23567"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.03.005"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121075"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_6_30_1","article-title":"Recycled Predictions\u201d for Computing Marginal Effects. SAS Global","author":"Li z","year":"2010","journal-title":"Forum"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx145"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes350"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22056"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.12.1472"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00058.x"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.08.001"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61704-9"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.017"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S148303"},{"key":"e_1_2_6_42_1","first-page":"161","article-title":"Understanding vaccination rates and attitudes among patients with rheumatoid arthritis","volume":"22","author":"Sandler DS","year":"2016","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22470"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39098"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23609"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:28:40Z","timestamp":1759418920000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/acr2.11376"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11376","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"2021-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}